ESGO 2021 | Personalized medicine for patients with gynecological sarcoma

Isabelle Ray-Coquard, MD, PhD, Léon Bérard Center, Lyon, France, highlights the state of the art of personalized patients for patients with gynecological sarcoma, which represent 3% to 4% of all gynecological malignancies and 13% of all sarcomas. Prof. Ray-Coquard discusses different molecular and pathological subtypes seen in gynecological sarcoma, as well as the aim for targeted therapies for this patient population. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague.